Evidence map›Paper›PMID 41909729›Full record

ArticleActa pharmaceutica Sinica. B2026

Identification of a small-molecule targeting PLAGL2 DNA-binding domain inhibits extracellular matrix formation and enhances lenvatinib sensitivity in hepatocellular carcinoma.

Weiwei Hu, Jiaping Ni, Shufang Zheng, Xiaohui Wei, Dongqing Zhai, Jinglin Qi, Xinqi Ye, Mingyin Lu, Hanrui Bian, Jintong Li and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Weiwei HuInstitute of Translational Medicine, China Pharmaceutical University, Nanjing 210009, China.
Jiaping NiInstitute of Translational Medicine, China Pharmaceutical University, Nanjing 210009, China.
Shufang ZhengInstitute of Translational Medicine, China Pharmaceutical University, Nanjing 210009, China.
Xiaohui WeiState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Dongqing ZhaiInstitute of Translational Medicine, China Pharmaceutical University, Nanjing 210009, China.
Jinglin QiInstitute of Translational Medicine, China Pharmaceutical University, Nanjing 210009, China.
Xinqi YeInstitute of Translational Medicine, China Pharmaceutical University, Nanjing 210009, China.
Mingyin LuInstitute of Translational Medicine, China Pharmaceutical University, Nanjing 210009, China.
Hanrui BianInstitute of Translational Medicine, China Pharmaceutical University, Nanjing 210009, China.
Jintong LiInstitute of Translational Medicine, China Pharmaceutical University, Nanjing 210009, China.
Yumeng ShenState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
Jingwei JiangShuangYun BioMed Sci and Tech (Suzhou) Co., Ltd., Suzhou 21500, China.
Weijun ZhaoInstitute of Translational Medicine, China Pharmaceutical University, Nanjing 210009, China.
Xueqing ShaoState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Shihao XuState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Xuewu LiangState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Hong LiuState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Yong YangInstitute of Translational Medicine, China Pharmaceutical University, Nanjing 210009, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The increased stiffness of the extracellular matrix (ECM) is known to promote the progression of hepatocellular carcinoma (HCC). Currently, there are no approved therapies for targeting ECM sensors and remodelers. The objective of this study was to identify the molecular mechanisms underlying the role of Pleomorphic adenoma gene-like 2 (PLAGL2) in HCC ECM remodeling and to formulate compounds that effectively inhibit PLAGL2 transcriptional regulation. Our work revealed that PLAGL2 remodeled the ECM produced by HCC cells

Indexed as

Extracellular matrix remodelingHepatic stellate cellsHepatocellular carcinomaLenvatinib

Identifiers

PMID41909729
PMCPMC13031157

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.